Entrada Therapeutics (TRDA)
Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.
Something off on this page? Send us feedback.
Develops therapies built on a cyclic-peptide delivery platform that shuttles oligonucleotides into cells, applying it first to exon-skipping treatments for Duchenne muscular dystrophy and, through a partnership with Vertex Pharmaceuticals, to myotonic dystrophy type 1; no therapy has reached the market and collaboration payments remain the primary revenue source.
Uses a cyclic-peptide delivery platform, the Endosomal Escape Vehicle, to carry oligonucleotides past the cell membrane and out of the endosome into the cytosol, reaching disease targets inside cells rather than on the surface.
The lead franchise applies that platform to exon-skipping oligonucleotides for Duchenne muscular dystrophy, with candidates targeting exons 44, 45, 50 and 51; the exon-44 program is furthest along, in clinical trials outside and inside the US.
A separate program for myotonic dystrophy type 1 advances through a partnership with Vertex Pharmaceuticals, which funds and runs an early-stage global trial and has been the primary source of revenue to date.
A multiyear US clinical hold on the exon-44 program, lifted in 2025 after supporting data gathered outside the country, delayed domestic trials; no therapy has yet reached the market.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 12, 2026 | Roth Capital | Reiterate | Rating: —Target: $10 | Target: $11 |
| Jun 8, 2026 | Guggenheim | Reiterate | Rating: —Target: $20 | Target: $17 |
| May 8, 2026 | Roth Capital | Target | Target: $13 | Target: $10 |
| May 8, 2026 | HC Wainwright & Co. | Downgrade | ||
| Feb 10, 2026 | Guggenheim | Target | Target: — | Target: $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $223.0M · Total debt $48.5M · Total assets $298.9M · Shareholders' equity $233.4M
- Revenue
- $898.0K
- Operating income
- −$45.0M
- Net income
- −$42.8M
No dividends on record.
| Institutions | ≈ 75.17% | 29.27M shares | |
|---|---|---|---|
| 130 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 22.87% | 8.90M shares | |
| 8 holders · as of Sep 9, 2026 | |||
| Strategic holders | 21.48% | 8.36M shares | |
| 3 holders · as of Aug 10, 2026 | |||
| Adds to | 119.52% | ||
38.94M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 119.52%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Baker Bros. Advisors LPInstitution | 13.03% | 5.07M | as of Jun 30, 2026 |
5Am Venture Management, LLCInstitution | 10.42% | 4.06M | as of Jun 30, 2026 |
BioVentures 2014 L.P. MPMInsider10 percent owner | 9.98% | 3.89M | filed Sep 9, 2026 |
5AM Ventures V, L.P.Strategic10 percent owner | 9.96% | 3.88M | filed Aug 10, 2026 |
Kush Parmar1Insiderdirector | 9.89% | 4.12M | filed Aug 10, 2026 |
- Kush Parmar's transaction reports restate only vehicles that traded; the 2025 ownership statement (4.12M) less the 271.7K net shares sold since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 9, 2026 | BioVentures 2014 L.P. MPM | 10 percent owner | −28,837 | $7.13 |
| Sep 8, 2026 | BioVentures 2014 L.P. MPM | 10 percent owner | −192,500 | $7.41 |
| Sep 4, 2026 | BioVentures 2014 L.P. MPM | 10 percent owner | −38,500 | $7.11 |
| Sep 9, 2026 | Bioventures 2018 L.p. Mpm | 10 percent owner | −28,837 | $7.13 |
| Sep 8, 2026 | Bioventures 2018 L.p. Mpm | 10 percent owner | −192,500 | $7.41 |
- Sarepta Therapeutics
Head-to-head in DMD exon-skipping with approved products across exons 45/51.
- Dyne Therapeutics
Antibody-fragment delivery platform racing ahead on exon 51 and DM1.
- PepGen
Peptide-conjugate delivery rival, now concentrated in DM1 after exiting DMD.
- Wave Life Sciences
Exon-53 DMD program on a rival stereopure oligonucleotide platform.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Entrada Therapeutics | $6.53 | −2.68% | $260.5M | — | — | 55.6 | −54.0% |
| Sarepta Therapeutics | $20.42 | −1.87% | $2.20B | — | 35.5 | 1.1 | −34.3% |
| Dyne Therapeutics | $16.86 | −1.63% | $3.20B | — | — | — | — |
| PepGen | $2.87 | −3.86% | $206.1M | — | — | — | — |
| Wave Life Sciences | $4.07 | −6.55% | $857.2M | — | — | 13.1 | −73.9% |
| Median | — | 35.5 | 7.1 | −54.1% |